-+ 0.00%
-+ 0.00%
-+ 0.00%

IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026

Barchart·12/29/2025 10:10:00
Listen to the news

Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing

New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.